Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Momenta Pharmaceuticals Inc. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, indicating a focused but slightly varied technical scope. The portfolio involves 4 distinct examiners, which suggests that the 5 pending actions are not concentrated under a single individual's review. This distribution across 4 distinct examiners provides a range of perspectives within the 3 distinct art units.
The busiest examiner for this portfolio is DAHLE, CHUN WU, who is responsible for 2 pending office actions. This examiner handles a portion of the 5 total actions compared to the other distinct examiners involved. Practitioners should note that while the 3 distinct art units suggest technical consistency, the distribution of 5 actions among 4 examiners requires monitoring multiple individual prosecution styles simultaneously. The 2 actions under DAHLE, CHUN WU represent the concentration of activity for the current portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 2 | 50.2% | +51.1% |
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909282 | METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN | RAGHU, GANAPATHIRAM | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909282 | METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN | RAGHU, GANAPATHIRAM | 23d |
| 18520171 | ENGINEERED Fc CONSTRUCTS | DAHLE, CHUN WU | — |
| 18351827 | FcRn Antibodies and Methods of Use Thereof | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1653 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18520171 | ENGINEERED Fc CONSTRUCTS | DAHLE, CHUN WU | 1641 | §102DP | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18351827 | FcRn Antibodies and Methods of Use Thereof | DAHLE, CHUN WU | 1641 | §112DP | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18022061 | HYPERSIALYLATED IMMUNOGLOBULIN | BOWERS, ERIN M | 1653 | §103 | Final Rejection | 8d | Pending | Feb 17, 2023 |
| 17909282 | METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN | RAGHU, GANAPATHIRAM | 1652 | §103§112Other | Non-Final OA | 23d | Pending | Sep 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMomenta Pharmaceuticals Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Chun Wu Dahle has the most, with 2 of Momenta Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
